Progress in meeting today's demands in genital herpes: an overview of current management.
Treatment of genital herpes requires accurate diagnosis, patient support, and effective treatment. Diagnosis is usually straightforward for classic presentations characterized by vesicular lesions but can be challenging for atypical presentations, which are more common. Diagnosis of asymptomatic infection requires access to molecular technology or type-specific serologic assays. Misconceptions about herpes simplex infection are common and patient education is essential. Patient concerns extend beyond disease frequency and severity-the psychological impact should not be underestimated. Antiviral therapy is relevant at all stages of infection. Acyclovir, valacyclovir, and famciclovir are effective and well tolerated for genital herpes treatment. Continuous suppressive therapy controls all symptoms of recurrent disease and helps to relieve disease complications. The prodrugs valacyclovir and famciclovir offer easier, less-frequent dosing than required for acyclovir. Valacyclovir achieves effective suppression when taken once a day. Interventions to prevent genital herpes transmission and to control the global problem are urgently required.
D015075:2-Aminopurine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000188:drug therapy; D000208:Acute Disease; D000212:Acyclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D000077595:Famciclovir; D015658:HIV Infections / Q000150:complications; D006558:Herpes Genitalis / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D018259:Herpesvirus 1, Human; D018258:Herpesvirus 2, Human; D006801:Humans; D007121:Immunocompetence; D010353:Patient Education as Topic; D011355:Prodrugs / Q000008:administration & dosage / Q000627:therapeutic use*; D055502:Secondary Prevention; D016896:Treatment Outcome; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000914:Antibodies, Viral; D000998:Antiviral Agents; D011355:Prodrugs; D015075:2-Aminopurine; D014633:Valine; D000077483:Valacyclovir; D000077595:Famciclovir; D000212:Acyclovir